| Lived experience submissions on new treatments and medicines, part of national working group looking at HTA reform, part of industry campaign to improve timeliness of HTA approval [Australia]. | 呼吸器
> 肺疾患 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | Over 100,000 | National | Regularly | 119011106646 |
| Work with PBAC [Pharmaceutical Benefits Advisory Committee], HTA [Health Technology Assessment], TGA [Therapeutic Goods Administration], and MSAC [Medical Services Advisory Committee], as well as patient groups and Medicines Australia Australia to advocate for access and equity for treatments and care. | 神経筋
> 筋ジストロフィー | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 1,000 | National | Regularly | 119021570524 |
| We support and advocate for enhancement of the involvement of patients/carers in Health Technology. We have been involved in the Co design group Enhancing Consumer involvement in Australian Health technology assessment and in the HTA Review process. | がん
> がん：ほとんどの種類 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | We do not communicate with patients directly | Regional | Sometimes | 119031444677 |
| Consumer feedback to PBAC [Pharmaceutical Benefits Advisory Committee], MSAC [Medical Services Advisory Committee], government consultations, and other organisations on behalf of those with kidney disease. | 腎臓
> 腎臓病 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | Do not know | National | Regularly | 119051003447 |
| We provide public comment to the Pharmaceutical Benefits Advisory Committee [PBAC] for the reimbursement of medicines relating to asthma, including some vaccines. | 呼吸器
> 喘息 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | Over 100,000 | National | Regularly | 119051065145 |
| PBAC [Pharmaceutical Benefits Advisory Committee] comments. | スキン
> アトピー性皮膚炎/湿疹 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | Over 100,000 | National | Regularly | 119051082840 |
| HTA [Health Technology Assessment] — lived experience. | 呼吸器
> 肺疾患 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | Over 100,000 | National | Regularly | 119051865995 |
| We provide expertise to regulatory and funding decision-makers on topics like newborn screening, medicine listing, and model of care funding. | レア
> まれな疾患：遺伝性 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 1,000 | National | Sometimes | 119054286714 |
| Involved in government [Australia] policy reviews - HTA review and Chronic Disease - submit responses to TGA [Therapeutic Goods Administration], MSAC [Medical Services Advisory Committee], and PBAC [Pharmaceutical Benefits Advisory Committee] in relation to sponsor requests. | 消化器系
> IBD | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | Over 100,000 | National | Regularly | 119058351283 |
| PBAC [Pharmaceutical Benefits Advisory Committee], MSAC [Medical Services Advisory Committee], PL [Prostheses List]. | 心臓血管
> 心臓・循環器系の疾患 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | Do not know | International | Regularly | 119061299937 |
| Our organisation exists to represent the interests of both community-led mental health service organisations and also the lived experience consumer community. A recent example of our work representing patient interests to regulators that are responsible for deciding drug pricing was recent correspondence we issued to the Australian Pharmaceutical Benefits Advisory Committee, requesting that a drug for the treatment of schizophrenia be listed on the Pharmaceutical Benefits Scheme. In this correspondence, we directly represented the views of patients and family and carers. | メンタルヘルス
> メンタルヘルス：ほとんどの状態 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 10,000 | National | Sometimes | 119074282308 |
| We provide public comment to the Pharmaceutical Benefits Advisory Committee for the reimbursement of medicines relating to asthma, including some vaccines. We write and support submissions to the Therapeutic Goods Administration for changes to medicines. Asthma Australia will lobby government if a change that is made is not in the best interest of people with asthma. | 呼吸器
> 喘息 | 規制上のパートナーシップ
> マーケティング承認申請への貢献 | Over 100,000 | National | Regularly | 119051065145 |
| Work with PBAC [Pharmaceutical Benefits Advisory Committee], HTA [Health Technology Assessment], TGA [Therapeutic Goods Administration], and MSAC [Medical Services Advisory Committee], as well as patient groups and Medicines Australia Australia to advocate for access and equity for treatments and care. | 神経筋
> 筋ジストロフィー | 規制上のパートナーシップ
> 政策立案者・規制当局との会議への出席・ファシリテーション | 1,000 | National | Regularly | 119021570524 |
| Our organisation exists to represent the interests of both community-led mental health service organisations and also the lived experience consumer community. | メンタルヘルス
> メンタルヘルス：ほとんどの状態 | 規制上のパートナーシップ
> 他の医療擁護者と | 10,000 | National | Sometimes | 119074282308 |
| Regular advocacy and lobbying to all levels of government on new and current diabetes medications and technology. | 内分泌
> 糖尿病（1型および2型の両方） | 政策と法律への影響
> 医療政策と法律に影響を与える | Over 100,000 | National | Regularly | 119023443093 |
| We provide public comment to the Pharmaceutical Benefits Advisory Committee for the reimbursement of medicines relating to asthma, including some vaccines. We write and support submissions to the Therapeutic Goods Administration for changes to medicines. Asthma Australia will lobby government if a change that is made is not in the best interest of people with asthma. | 呼吸器
> 喘息 | 政策と法律への影響
> 医療政策と法律に影響を与える | Over 100,000 | National | Regularly | 119051065145 |
| Involved in government [Australia] policy reviews - HTA review and Chronic Disease - submit responses to TGA [Therapeutic Goods Administration], MSAC [Medical Services Advisory Committee], and PBAC [Pharmaceutical Benefits Advisory Committee] in relation to sponsor requests. | 消化器系
> IBD | 政策と法律への影響
> 医療政策と法律に影響を与える | Over 100,000 | National | Regularly | 119058351283 |
| Where possible, we add our advocacy voice to decision-makers. | 神経筋
> 筋ジストロフィー | 政策と法律への影響
> 医療政策と法律に影響を与える | 1,000 | National | Rarely | 119070072574 |
| Consumer feedback to PBAC [Pharmaceutical Benefits Advisory Committee], MSAC [Medical Services Advisory Committee], government consultations, and other organisations on behalf of those with kidney disease. | 腎臓
> 腎臓病 | 政策と法律への影響
> 公聴会やパブリックコンサルテーションに参加する | Do not know | National | Regularly | 119051003447 |
| Public submissions. | 医学研究
> 医学研究 | 政策と法律への影響
> 公聴会やパブリックコンサルテーションに参加する | 100 | National | Sometimes | 119075599019 |
| Pre-Budget Submissions, Advocacy activities, Meetings. | リウマチ性
> リウマチ性疾患：ほとんどの種類 | 政策と法律への影響
> 国会議員や政治指導者を動員する | Over 100,000 | National | Regularly | 119017682842 |
| Weight loss drugs, general medicine costs. | 患者擁護
> 患者の権利 | 価格設定と手頃な価格の擁護
> 公正な医薬品価格の実現を推進する | 100,000 | National | Sometimes | 119055318270 |
| Involved in government [Australia] policy reviews - HTA review and Chronic Disease - submit responses to TGA [Therapeutic Goods Administration], MSAC [Medical Services Advisory Committee], and PBAC [Pharmaceutical Benefits Advisory Committee] in relation to sponsor requests. | 消化器系
> IBD | 価格設定と手頃な価格の擁護
> 公正な医薬品価格の実現を推進する | Over 100,000 | National | Regularly | 119058351283 |
| Pricing. | リウマチ性
> 全身性エリテマトーデス | 価格設定と手頃な価格の擁護
> 公正な医薬品価格の実現を推進する | 5,000 | International | Regularly | 119058972997 |
| Through an HTA [Health Technology Assessment] implementation review, direct advocacy around drug access and pricing, part of roundtables to more effectively advocate patient interests for change. | 神経学的
> 神経学的：その他 | 価格設定と手頃な価格の擁護
> 公正な医薬品価格の実現を推進する | We do not communicate with patients directly | National | Regularly | 119069368666 |
| We will sometimes complete Consumer Comments for the Pharmaceutical Benefits Advisory Committee if we feel that an immunization should be federally funded on the National Immunization Program. | 感染性
> 予防接種 | 価格設定と手頃な価格の擁護
> 製品の償還リスト/国家医薬品集への収載推進 | Over 100,000 | National | Sometimes | 119022383972 |
| Access to Palovarotene [to reduce the formation of abnomal bone tissue in people with It is indicated for patients with the ultra-rare genetic disorder Fibrodysplasia Ossificans Progressiva (FOP)] via the PBS [Pharmaceutical Benefits Scheme] listing. | ボーン
> 進行性骨化性線維異形成症（FOP） | 価格設定と手頃な価格の擁護
> 製品の償還リスト/国家医薬品集への収載推進 | 100 | National | Rarely | 119044789085 |
| Australia's PBS [Pharmaceutical Benefits Scheme] listings as an example. | 腎臓
> 腎臓病 | 価格設定と手頃な価格の擁護
> 製品の償還リスト/国家医薬品集への収載推進 | 5,000 | National | Regularly | 119050789619 |
| We provide expertise to regulatory and funding decision-makers on topics like newborn screening, medicine listing, and model of care funding. | レア
> まれな疾患：遺伝性 | 価格設定と手頃な価格の擁護
> 製品の償還リスト/国家医薬品集への収載推進 | 1,000 | National | Sometimes | 119054286714 |
| Our organisation exists to represent the interests of both community-led mental health service organisations and also the lived experience consumer community. A recent example of our work representing patient interests to regulators that are responsible for deciding drug pricing was recent correspondence we issued to the Australian Pharmaceutical Benefits Advisory Committee, requesting that a drug for the treatment of schizophrenia be listed on the Pharmaceutical Benefits Scheme. In this correspondence, we directly represented the views of patients and family and carers. | メンタルヘルス
> メンタルヘルス：ほとんどの状態 | 価格設定と手頃な価格の擁護
> 製品の償還リスト/国家医薬品集への収載推進 | 10,000 | National | Sometimes | 119074282308 |
| Work with PBAC [Pharmaceutical Benefits Advisory Committee], HTA [Health Technology Assessment], TGA [Therapeutic Goods Administration], and MSAC [Medical Services Advisory Committee], as well as patient groups and Medicines Australia Australia to advocate for access and equity for treatments and care. | 神経筋
> 筋ジストロフィー | アクセス経路の改善
> 医薬品・医療への公平なアクセスを促進する | 1,000 | National | Regularly | 119021570524 |
| Weight loss drugs, general medicine costs. | 患者擁護
> 患者の権利 | アクセス経路の改善
> 医薬品・医療への公平なアクセスを促進する | 100,000 | National | Sometimes | 119055318270 |
| Regulations and restrictions regarding prescribing of antivirals for COVID to our patient cohort [neurological conditions]. | 神経学的
> 神経学的：その他 | アクセス経路の改善
> 医薬品・医療への公平なアクセスを促進する | 5,000 | National | Rarely | 119056702514 |
| PBAC [Pharmaceutical Benefits Advisory Committee], MSAC [Medical Services Advisory Committee], PL [Prostheses List]. | 心臓血管
> 心臓・循環器系の疾患 | アクセス経路の改善
> 医薬品・医療への公平なアクセスを促進する | Do not know | International | Regularly | 119061299937 |
| Through an HTA [Health Technology Assessment] implementation review, direct advocacy around drug access and pricing, part of roundtables to more effectively advocate patient interests for change. | 神経学的
> 神経学的：その他 | アクセス経路の改善
> 医薬品・医療への公平なアクセスを促進する | We do not communicate with patients directly | National | Regularly | 119069368666 |
| Through an HTA [Health Technology Assessment] implementation review. | 神経学的
> 神経学的：その他 | アクセス経路の改善
> 医薬品・医療への公平なアクセスを促進する | We do not communicate with patients directly | National | Regularly | 119069368666 |
| We will sometimes complete Consumer Comments for the Pharmaceutical Benefits Advisory Committee if we feel that an immunization should be federally funded on the National Immunization Program. | 感染性
> 予防接種 | アクセス経路の改善
> より広いワクチンアクセスを推進する | Over 100,000 | National | Sometimes | 119022383972 |
| Access to Palovarotene [to reduce the formation of abnomal bone tissue in people with It is indicated for patients with the ultra-rare genetic disorder Fibrodysplasia Ossificans Progressiva (FOP)] via the PBS [Pharmaceutical Benefits Scheme] listing. | ボーン
> 進行性骨化性線維異形成症（FOP） | アクセス経路の改善
> 希少・超希少疾患治療へのアクセス改善 | 100 | National | Rarely | 119044789085 |
| Consumer feedback to PBAC [Pharmaceutical Benefits Advisory Committee], MSAC [Medical Services Advisory Committee], government consultations, and other organisations on behalf of those with kidney disease. | 腎臓
> 腎臓病 | エビデンスに基づく患者の意見
> 患者のインサイトを活用して意思決定に役立てる | Do not know | National | Regularly | 119051003447 |
| Lived experience submissions on new treatments and medicines, part of national working group looking at HTA reform, part of industry campaign to improve timeliness of HTA approval [Australia]. | 呼吸器
> 肺疾患 | エビデンスに基づく患者の意見
> 患者の体験談や生きた経験のナラティブを活用する | Over 100,000 | National | Regularly | 119011106646 |
| We support and advocate for enhancement of the involvement of patients/carers in Health Technology. We have been involved in the Co design group Enhancing Consumer involvement in Australian Health technology assessment and in the HTA Review process. | がん
> がん：ほとんどの種類 | エビデンスに基づく患者の意見
> 患者の体験談や生きた経験のナラティブを活用する | We do not communicate with patients directly | Regional | Sometimes | 119031444677 |
| HTA [Health Technology Assessment] — lived experience. | 呼吸器
> 肺疾患 | エビデンスに基づく患者の意見
> 患者の体験談や生きた経験のナラティブを活用する | Over 100,000 | National | Regularly | 119051865995 |
| Our organisation exists to represent the interests of both community-led mental health service organisations and also the lived experience consumer community. A recent example of our work representing patient interests to regulators that are responsible for deciding drug pricing was recent correspondence we issued to the Australian Pharmaceutical Benefits Advisory Committee, requesting that a drug for the treatment of schizophrenia be listed on the Pharmaceutical Benefits Scheme. In this correspondence, we directly represented the views of patients and family and carers. | メンタルヘルス
> メンタルヘルス：ほとんどの状態 | エビデンスに基づく患者の意見
> 患者の体験談や生きた経験のナラティブを活用する | 10,000 | National | Sometimes | 119074282308 |
| Pricing, clinical trials. | リウマチ性
> 全身性エリテマトーデス | 診断と薬の配達
> 臨床試験デザインの共同作業 | 5,000 | International | Regularly | 119058972997 |
| We provide expertise to regulatory and funding decision-makers on topics like newborn screening, medicine listing, and model of care funding. | レア
> まれな疾患：遺伝性 | 診断と薬の配達
> スクリーニングと早期発見のサポート | 1,000 | National | Sometimes | 119054286714 |
| We provide expertise to regulatory and funding decision-makers on topics like newborn screening, medicine listing, and model of care funding. | レア
> まれな疾患：遺伝性 | 機関ガバナンス
> 政府の諮問機関における代表性を確保する | 1,000 | National | Sometimes | 119054286714 |
| Preterm Infants Parents Association [PIPA] has representatives on numerous hospital and Queensland Health Department committees. | 子どもの健康
> 新生児 | 機関ガバナンス
> 政府の諮問機関における代表性を確保する | 5,000 | Regional | Regularly | 119074312093 |
| Through an HTA [Health Technology Assessment] implementation review, direct advocacy around drug access and pricing, part of roundtables to more effectively advocate patient interests for change. | 神経学的
> 神経学的：その他 | 機関ガバナンス
> マルチステークホルダーネットワーク内での効果的な協働 | We do not communicate with patients directly | National | Regularly | 119069368666 |
インタラクション
アクションと支援活動
14 メンション
